SGEN Seattle Genetics, Inc.

65.50
+0.2  (0.31%)
Previous Close 65.30
Open 64.93
Price To book 14.61
Market Cap 9.29B
Shares 141,869,000
Volume 519,080
Short Ratio 10.00
Av. Daily Volume 1,201,150

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial placed on clinical hold - announced December 27, 2016.
Vadastuximab Talirine (SGN-CD33A)
Frontline Acute Myeloid Leukemia (AML)
Approved August 18, 2015 under priority review
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Phase 3 initiated May 2016. Enrollment ongoing as of February 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
Phase 3 data due in 2017.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
Phase 3 enrollment completed November 2016. Data are due 2017 or 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Phase 3 data released August 2016. sNDA to be filed mid 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma

Latest News

  1. SEATTLE GENETICS INC /WA Files SEC form 10-K, Annual Report
  2. 7 Stocks That Are Beating the Market
  3. Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer
  4. VenBio Tries to Block Immunomedics Cancer Deal
  5. SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  6. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN
  7. SEATTLE GENETICS INC /WA Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat
  8. SGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  9. SGEN NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors of Important Deadline in Class Action – SGEN
  10. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  11. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017
  12. Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
  13. Seattle Genetics signs $2B licensing deal with Immunomedics for cancer drug
  14. SGEN SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  15. DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm
  16. Activist Investor to Block Partnership of Immunomedics and Seattle Genetics
  17. Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: 2016 By the Numbers : February 14, 2017
  18. Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics
  19. Seattle Genetics Earnings: Waiting on ECHELON
  20. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm
  21. SGEN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017
  22. Here’s Our Take On The Immunomedics, Inc. (IMMU) Deal
  23. Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors
  24. Seattle Genetics reports 4Q loss
  25. Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma
  26. Biogen and Fitbit trade higher while Endologix tumbles
  27. Seattle Genetics' cancer drug put on clinical hold after 4 deaths
  28. Seattle Genetics' cancer drug put on clinical hold after 4 deaths
  29. Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A)
  30. Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
  31. Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
  32. Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma
  33. Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma
  34. Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma
  35. Seattle Genetics Announces ASH 2016 Abstracts Highlighting Company’s Expanding Global Leadership in the Development of Innovative Antibody-Drug Conjugates
  36. Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting
  37. Seattle Genetics Reports Third Quarter 2016 Financial Results
  38. Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ISHL 2016
  39. Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
  40. Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
  41. Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood
  42. Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting